Dissolving microneedles for intradermal vaccination: manufacture, formulation, and stakeholder considerations

Dissolving microneedle (DMN) arrays are minimally invasive
devises that consist of a series of microscopic needles on a base
support. Upon insertion into the skin, the needles dissolve depositing
their payload (Figure 1(A–C)) [1]. DMN have received substantial
interest for intradermal vaccination due to their ease of use
and possibility for self-administration. DMN research is close to
commercialization. However, moving forward, there remain a
number of concerns which warrant investigation. Herein, such
considerations are discussed with a specific focus on the key
challenges for DMN industrialization being highlighted.